Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 5.1 Exhibit 5.1
- 10.7 Exhibit 10.7(B)
- 10.18 Exhibit 10.18
- 10.19 Exhibit 10.19
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 99.3 Exhibit 99.3
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 107 Exhibit 107
- Download Excel data file
- View Excel data file
Associated filings
- 29 Jul 22 424B3 Prospectus supplement
- 29 Jul 22 EFFECT Notice of effectiveness
- 26 Jul 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 Jun 22 S-4 Registration of securities issued in business combination transactions
LSTA similar filings
- 26 Jul 22 Registration of securities issued in business combination transactions (amended)
- 15 Jun 22 Registration of securities issued in business combination transactions
- 2 Sep 11 Registration of securities issued in business combination transactions
- 3 Dec 10 Registration of securities issued in business combination transactions (amended)
- 30 Nov 10 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our report dated March 22, 2022, with respect to the consolidated financial statements of Caladrius Biosciences, Inc. contained in the Registration Statement and Prospectus. We consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the caption “Experts.”
/s/ GRANT THORNTON LLP
New York, New York
June 15, 2022